How will the pharma marketing, educational and service model adapt in response to redefined value in immuno-oncology? Phil Ford, Managing Director at Litmus Medical Communications, a Syneos HealthTM company and Andrew Thomas, Head of Integrated Communications, Europe at Syneos HealthTM, explore for PMLiVE.